webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More
  1. Home
  2. Products
  3. ADC Cytotoxin with Linker
  4. DBM(C6)-VC-PAB-MMAE

DBM(C6)-VC-PAB-MMAE

  CAS No.: 1644228-55-6   Cat No.: BADC-01408 4.5  

DBM(C6)-VC-PAB-MMAE is a thiol-reactive drug-linker conjugate used in the synthesis of antibody-drug conjugates (ADCs).

DBM(C6)-VC-PAB-MMAE

Structure of 1644228-55-6

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Cytotoxin with Linker
Molecular Formula
C68H103Br2N11O15
Molecular Weight
1474.44

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
L-Valine, N-[[[4-[[N-[6-(3,4-dibromo-2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]-N-methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-; N-[[[4-[[N-[6-(3,4-Dibromo-2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]-N-methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valine
IUPAC Name
4-((S)-2-((S)-2-(6-(3,4-dibromo-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-3-methylbutanamido)-5-ureidopentanamido)benzyl ((S)-1-(((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)(methyl)carbamate
Canonical SMILES
O=C(N)NCCCC(NC(=O)C(NC(=O)CCCCCN1C(=O)C(Br)=C(Br)C1=O)C(C)C)C(=O)NC2=CC=C(C=C2)COC(=O)N(C)C(C(=O)NC(C(=O)N(C)C(C(OC)CC(=O)N3CCCC3C(OC)C(C(=O)NC(C)C(O)C=4C=CC=CC4)C)C(C)CC)C(C)C)C(C)C
InChI
InChI=1S/C68H103Br2N11O15/c1-15-41(8)57(49(94-13)36-51(83)80-35-23-27-48(80)59(95-14)42(9)60(85)73-43(10)58(84)45-24-18-16-19-25-45)78(11)66(91)55(39(4)5)77-63(88)56(40(6)7)79(12)68(93)96-37-44-29-31-46(32-30-44)74-61(86)47(26-22-33-72-67(71)92)75-62(87)54(38(2)3)76-50(82)28-20-17-21-34-81-64(89)52(69)53(70)65(81)90/h16,18-19,24-25,29-32,38-43,47-49,54-59,84H,15,17,20-23,26-28,33-37H2,1-14H3,(H,73,85)(H,74,86)(H,75,87)(H,76,82)(H,77,88)(H3,71,72,92)/t41-,42+,43+,47-,48-,49+,54-,55-,56-,57-,58+,59+/m0/s1
InChIKey
HUVBFPTZLBVBAA-KKUITVJMSA-N
Density
1.310±0.06 g/cm3
Boiling Point
1375.2±65.0°C at 760 mmHg

DBM(C6)-VC-PAB-MMAE, a potent antibody-drug conjugate (ADC) linker-payload system revolutionizing cancer therapeutics, introduces a groundbreaking approach for targeted treatment.

Targeted Cancer Therapy: Precision-engineered to transport cytotoxic agents directly to cancerous cells while minimizing harm to healthy tissues, DBM(C6)-VC-PAB-MMAE achieves unparalleled accuracy. By linking the payload to antibodies recognizing specific cancer cell surface markers, the payload is unleashed upon internalization, initiating precise cellular destruction with exceptional precision.

Overcoming Drug Resistance: In the realm of cancer treatment, DBM(C6)-VC-PAB-MMAE emerges as a beacon of hope in overcoming resistance encountered in conventional chemotherapy regimens. By exploiting unique biomarkers present on drug-resistant cancer cells, this ADC circumvents resistance mechanisms and efficiently delivers its cytotoxic payload. This strategic maneuver enhances therapeutic effectiveness, particularly in resistant cancer subtypes.

Improved Therapeutic Index: Pioneering cancer therapeutics, ADC technology embodied by DBM(C6)-VC-PAB-MMAE elevates the therapeutic index by offering increased efficacy at lower doses, thereby reducing systemic toxicity. By selectively releasing the cytotoxic agent in the tumor microenvironment, healthy cells are spared, resulting in fewer side effects and enhanced patient outcomes.

Combination Therapy: Embracing a multifaceted strategy in cancer care, DBM(C6)-VC-PAB-MMAE can be combined with complementary modalities, like immune checkpoint inhibitors, to amplify anticancer effects. This synergistic fusion shows potential in reducing tumor size or reshaping the tumor microenvironment to heighten responsiveness to immunotherapy.

What is DBM(C6)-VC-PAB-MMAE?

DBM(C6)-VC-PAB-MMAE is a linker-payload construct for ADCs, featuring a valine-citrulline peptide linker attached to the potent microtubule inhibitor MMAE. The C6 spacer improves solubility and conjugation efficiency with antibodies.

27/5/2019

We are interested in how DBM(C6)-VC-PAB-MMAE releases its payload.

Upon internalization of the ADC, lysosomal proteases cleave the VC-PAB linker, triggering the release of MMAE. The C6 spacer does not interfere with enzymatic cleavage but enhances the overall solubility and flexibility of the conjugate.

27/9/2017

Could you advise what stability features DBM(C6)-VC-PAB-MMAE offers?

DBM(C6)-VC-PAB-MMAE is designed for plasma stability to minimize premature payload release. The VC-PAB linker resists hydrolysis in circulation while maintaining efficient cleavage by lysosomal proteases in targeted cells.

5/3/2016

Could you kindly advise which antibodies are suitable for DBM(C6)-VC-PAB-MMAE conjugation?

DBM(C6)-VC-PAB-MMAE can be conjugated to antibodies with exposed cysteine residues or engineered sites. Its chemical design supports a controlled drug-to-antibody ratio (DAR), optimizing ADC pharmacokinetics and efficacy.

13/9/2018

Good afternoon! Could you advise in which therapeutic areas DBM(C6)-VC-PAB-MMAE is used?

DBM(C6)-VC-PAB-MMAE is used in ADC research against various cancers, including hematological malignancies and solid tumors. The potent MMAE payload enables targeting of low-antigen-density cells while minimizing off-target toxicity.

24/9/2022

— Dr. Anna Schultz, ADC Project Leader (Germany)

DBM(C6)-VC-PAB-MMAE provided consistent linker performance in cytotoxic payload conjugation. Excellent batch-to-batch reproducibility.

5/3/2016

— Mr. James Wilson, Bioconjugation Specialist (USA)

The linker DBM(C6)-VC-PAB-MMAE integrated efficiently into our ADC pipeline. Stability and solubility were outstanding.

24/9/2022

— Dr. Caroline Dupont, Senior Chemist (France)

BOC Sciences’ DBM(C6)-VC-PAB-MMAE allowed us to achieve high DAR ADCs without side reactions. Very reliable.

13/9/2018

— Prof. Richard Evans, Biochemistry Professor (UK)

We observed excellent reproducibility when using DBM(C6)-VC-PAB-MMAE across multiple ADC constructs. Highly recommend.

27/5/2019

— Dr. Laura Nielsen, Research Scientist (Denmark)

The product quality and handling instructions for DBM(C6)-VC-PAB-MMAE were exceptional, helping us accelerate conjugation studies.

— Mr. Thomas Reed, ADC Development Chemist (USA)

DBM(C6)-VC-PAB-MMAE met our expectations for purity and reaction efficiency, with minimal by-product formation.

27/9/2017

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Calculate
The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Calculate

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Payload Development Biological Payload ADC Linker–Payload Conjugation ADC Linker Development Chemical Payload Enzyme Cleavable Linker Cathepsin B Cleavable Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Maytansine and Its Analogues Linkers - A Crucial Factor in Antibody–Drug Conjugates Cytotoxic Agents Used in Antibody–Drug Conjugates Exatecan Mesylate in ADCs: A New Topo I Inhibitor What is Calicheamicin? What is Monomethyl Auristatin E (MMAE)? What is Monomethyl Auristatin F (MMAF)? What is Pyrrolobenzodiazepine (PBD)? Antiviral Potential of Thapsigargin in COVID-19 Research In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC Cytotoxin with Linker

ADC Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

ADC Linker

Precise Conjugation For Success

Antibody-Drug Conjugates (ADCs)

Antibody-Drug Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: Vc-seco-DUBA | Seco-DUBA hydrochloride | Mal-VC-PAB-DM1 | Propargyl-PEG1-SS-PEG1-C2-Boc | D-Val-D-Cit-PAB | Ansamitocin P 3' | Nα-Fmoc-Nε-(propargyloxy)carbonyl-L-lysine | Maytansinol | MC-betaglucuronide-MMAE-1 | Acetylene-linker-Val-Cit-PABC-MMAE | DBM(C6)-VC-PAB-MMAE
Send Inquiry
Verification code
Inquiry Basket
loading Loading ......
Delete selectedGo to checkout